Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
Drug Discovery and Development to focus on pharmaceutical trends

Drug Discovery and Development to focus on pharmaceutical trends

NIH awards three UNC Scientists for high risk and innovative research

NIH awards three UNC Scientists for high risk and innovative research

Galapagos announces BioFocus DPI's drug discovery collaboration with SPRI

Galapagos announces BioFocus DPI's drug discovery collaboration with SPRI

Philips and Bruker sign MOU to develop new imaging technology

Philips and Bruker sign MOU to develop new imaging technology

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART's new generation Optix MX3 optical molecular imaging system unveiled

Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

Livingston Securities announces the agenda for the 2nd Annual Livingston Healthcare Summit.

ACR Image Metrix successfully completes two years, looks forward to increased business in third year

ACR Image Metrix successfully completes two years, looks forward to increased business in third year

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Updates from Pacific Biosciences to its commercial strategy and progress

Updates from Pacific Biosciences to its commercial strategy and progress

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

Drug registration process for Nutra Pharma's pain reliever begins

Drug registration process for Nutra Pharma's pain reliever begins

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Cyntellect releases new cell cytometry system

Cyntellect releases new cell cytometry system

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Second-quarter 2009 unaudited results announced by Deltagen

Second-quarter 2009 unaudited results announced by Deltagen

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Helicos Biosciences to raise $10 million through private placement

Helicos Biosciences to raise $10 million through private placement

Cyntellect announces commercial availability of Stem Cell Manager

Cyntellect announces commercial availability of Stem Cell Manager

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.